4D Molecular Therapeutics, Inc.
FDMTNASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $775.10M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.96$16.93
- Volume (live)
- -
- Avg. volume (3M)
- 1.08M
4D Molecular Therapeutics (FDMT) Stock Price & Financial Analysis
4D Molecular Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.62 - $11.29 |
|---|---|
| 52-Week High | $16.93 |
| 52-Week Low | $6.96 |
| Open | $10.74 |
| Volume (last close) | 1.08M |
| Average Volume (3M) | 1.08M |
| Revenue (TTM) | 92.01M |
|---|---|
| Net Income (TTM) | -179.18M |
| Free Cash Flow (TTM) | -156.66M |
| EPS (TTM) | −$2.84 |
| Profit Margin | -194.74% |
| Operating Margin | -214.24% |
| Return on Equity (ROE) | -43.95% |
| Debt to Equity | 0.06 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 775.10M |
|---|---|
| Shares Outstanding | 70.27M |
| Price to Sales (P/S) | 8.42 |
| Price to Book (P/B) | 1.90 |
| EV/EBITDA | -4.15 |
| 50-Day MA | $13.98 |
|---|---|
| 200-Day MA | $10.70 |
| 1-Year Change | +18.50% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
4D Molecular Therapeutics at a Glance
As of the Oct 26, 2026 close, 4D Molecular Therapeutics (FDMT) has a market capitalization of $775.10M. The stock trades at 8.4× sales. Over the trailing twelve months it lost $179.18M on revenue of $92.01M and burned $156.66M of free cash flow. Revenue grew 278712.1% year over year.
As of its latest reported balance sheet, it holds $70.37M in cash and securities against $24.96M of debt, a net cash position of $45.41M.
4D Molecular Therapeutics does not currently pay a dividend.
The share price is up 18.5% over the past year. At $11.03 (the Oct 26, 2026 close) it sits within its 52-week range of $6.96 to $16.93, above its 200-day moving average of $10.70.
Based on 11 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $30.57, 177.2% above the Oct 26, 2026 close.
Frequently Asked Questions About 4D Molecular Therapeutics
What is the current stock price for FDMT?
As of the Oct 26, 2026 close, FDMT stock trades at $11.03. The 52-week range is $6.96–$16.93, with a day range of $10.62–$11.29.
What is the P/E ratio for FDMT?
The P/E ratio (Price-to-Earnings) for FDMT is shown in the Key Statistics section. This valuation metric helps compare 4D Molecular Therapeutics, Inc. to industry peers.
Does FDMT pay dividends?
4D Molecular Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for FDMT?
Based on ratings from 11 professional analysts over the last 90 days, the consensus for FDMT is Buy. The average 12-month price target is $30.57, a 177.2% upside from the Oct 26, 2026 close of $11.03.
What is the market cap of FDMT?
As of the Oct 26, 2026 close, 4D Molecular Therapeutics's market capitalization is $775.1M, classifying it as a small-cap company. 4D Molecular Therapeutics operates in the Healthcare sector within the Biotechnology industry.